# EDGAR Filing Document

**Accession Number:** 0001776197
**File Stem:** 0001776197-23-000007
**Filing Date:** 2023-3
**Character Count:** 26421
**Document Hash:** 001908e4893100b0b52220329f5a2735
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001776197-23-000007.hdr.sgml**: 20230316

**ACCESSION NUMBER**: 0001776197-23-000007

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20230316

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230316

**DATE AS OF CHANGE**: 20230316

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AKUMIN INC.
- **CENTRAL INDEX KEY:** 0001776197
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39479
- **FILM NUMBER:** 23739466

**BUSINESS ADDRESS:**
- **STREET 1:** 8300 W SUNRISE BLVD
- **CITY:** PLANTATION
- **STATE:** FL
- **ZIP:** 33322
- **BUSINESS PHONE:** 9546784489

**MAIL ADDRESS:**
- **STREET 1:** 8300 W SUNRISE BLVD
- **CITY:** PLANTATION
- **STATE:** FL
- **ZIP:** 33322

?xml version="1.0" ? aku-20230316

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

________________________________

**FORM 8-K**

________________________________

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported)**

**March 16, 2023**

________________________________

**Akumin Inc.**

**(Exact name of Registrant as specified in its charter)**

________________________________

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39479** | **88-4139425** |
| **(State or other jurisdiction<br>of incorporation)** | **(Commission<br>File Number)** | **(IRS Employer**<br>**Identification No.)** |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **8300 W. Sunrise Boulevard**<br> **Plantation**, **Florida** | **33322** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**(844) 730-0050**

**(Registrant's telephone number, including area code)**

**(Former name or former address, if changed since last report)**

________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered or to be registered pursuant to Section 12(b) of the Act.

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange<br>on which registered** |
| **Common Stock, $0.01 par value per share** | **AKU** | **The Nasdaq Stock Market LLC** |
| **Common Stock, $0.01 par value per share** | **AKU** | **Toronto Stock Exchange** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02 Results of Operations and Financial Condition.**

On March 16, 2023, Akumin Inc. issued a press release announcing results for the year ended December 31, 2022. See the press release attached as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | <u>[Press release dated](prakuminannouncesfull-year.htm)[M](prakuminannouncesfull-year.htm)[arch 16, 2023](prakuminannouncesfull-year.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **Akumin Inc.** | **Akumin Inc.** |
| Date: March 16, 2023 | By: | /s/ Riadh Zine |
|  |  | Riadh Zine<br>Chairman, Chief Executive Officer and Director |

---

## Exhibit 99.1

![image_0a.jpg](image_0a.jpg)***<br>Akumin Announces Full-Year 2022 Results and Provides 2023 Guidance***

March 16, 2023 – Plantation, FL – Akumin Inc. (NASDAQ/TSX: AKU) ("<u>Akumin</u>" or the "<u>Company</u>"), a national partner of choice for U.S. hospitals, health systems and physician groups, with comprehensive solutions addressing outsourced radiology and oncology service-line needs, announced today its financial results for the quarter and year ended December 31, 2022.

**Fourth Quarter 2022 Highlights**

• Akumin delivered fourth quarter same-store volume performance on a consolidated, pro forma basis as follows:

o-0.3% for MRI

o+7.8% for PET/CT

o+8.0% for Oncology Patient Starts

• The Company reported revenue totaling $184.6 million for the fourth quarter, a $5.2 million or 3% increase over the fourth quarter of last year. For the full year ended December 31, 2022, Akumin reported revenue of $749.6 million, a $328.6 million or 78% increase over the full year 2021. This year-over-year increase was primarily as a result of the Alliance HealthCare Services acquisition (the "Alliance Acquisition") which was completed on September 1, 2021.

• Net loss was $49.3 million and $151.6 million for the fourth quarter and year ended December 31, 2022, respectively, an increase in net loss of $22.7 million and $116.8 million, respectively, compared to the prior periods primarily due to higher interest expense, goodwill impairment charges, restructuring charges, and severance and related costs, partially offset by lower acquisition-related costs.

• Akumin generated $37.4 million of Adjusted EBITDA\* (as defined below) for the fourth quarter, a $9.9 million or 36% increase over the fourth quarter of last year. For the full year ended December 31, 2022, Akumin reported Adjusted EBITDA\* of $144.1 million, a $77.2 million or 115% increase over the full year 2021, primarily as a result of the Alliance Acquisition.

\*For a reconciliation of Adjusted EBITDA, which is a non-GAAP measure, to the most directly comparable GAAP financial measure, please see "Reconciliation of Non-GAAP Financial Measures".

------

*<u>Summary Consolidated Financial Results (in thousands, except for per share amounts)</u>*

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **3-month period ended<br>Dec 31, 2022** | **3-month period ended<br>Dec 31, 2021** | **<br>Year ended<br>Dec 31, 2022** | **<br>Year ended<br>Dec 31, 2021** |
| MRI Scans | 217 | 217 | 876 | 539 |
| PET-CT Scans | 34 | 32 | 133 | 46 |
| Oncology Patient Starts | 2.623 | 2.504 | 10.347 | 3.401 |
| Revenue | $184635 | $179443 | $749631 | $421079 |
| Net Loss | ($49331) | ($26632) | ($151587) | ($34814) |
| Adjusted EBITDA <sup>(1)</sup> | $37381 | $27522 | $144102 | $66903 |
| EPS –Diluted | $(0.46) | $(0.36) | $(1.75) | $(0.56) |

---

<sup>(1)</sup> See "Non-GAAP Measures" below.

Commenting on the year-end results, Riadh Zine, Chairman and Chief Executive Officer of the Company, said, "We are pleased that we were able to deliver strong financial results, within our updated guidance range for the quarter and full year. Our results are particularly impressive given that 2022 was a transformational year for Akumin during which we successfully integrated our $786 million acquisition of Alliance HealthCare Services. The integration comprised a number of initiatives including the implementation of a restructuring resulting in excess of $20 million of organizational savings in our first phase of transformation efforts, consolidated underperforming sites and completed a comprehensive review and repositioning of our oncology business.

"We also had to respond to several industry-wide challenges, including a shortage of clinical labor which negatively impacted our ability to generate same-store revenue growth, and unprecedented cost inflation, particularly in the areas of labor, third-party services, and medical supplies. Despite these challenges, we were able to deliver solid performance and have positioned the business for strong organic growth in 2023 and beyond.

"Our transformation initiatives are well underway and, as we stated in the third quarter, we believe both the second and third phases of our transformation efforts, which are focused on asset rationalization, consolidation, network integration, and purchasing power, are expected to result in more than $25 million in additional run-rate synergies during 2023, Zine continued.

"Akumin's vision is to be the partner of choice for health systems and hospitals by leveraging our dense network coverage to serve patients in their community, implementing best-in-class clinical standardization to improve patient care, and deploying technology to achieve operational excellence to enhance the patient experience," Mr. Zine concluded.

------

**Full-Year 2023 Financial Outlook**

Akumin is also pleased to announce today its full-year ending December 31, 2023 financial outlook. Akumin currently expects that the financial results of the Company for 2023 will be as follows:

---

| | |
|:---|:---|
| | **Akumin Full-Year 2023 Guidance** <sup>(1)</sup> |
| Revenue | $765-775mm |
| Adjusted EBITDA <sup>(2)</sup> | $150-160mm |
| Capex | $55-65mm |

---

<sup>(1)</sup> For additional information on forward-looking statements, see the section titled "Forward-Looking Information" below.

<sup>(2)</sup> See "Non-GAAP Measures" below.

Commenting on the 2023 financial outlook, Zine said, "While we have begun to see some improvement to the operating conditions we faced in 2022, some ongoing labor constraints and cost inflation persist in some of our markets which we have factored in to our outlook for 2023, notwithstanding the strong demand for our services which we expect to continue. We are confident in our ability to deliver solid results in 2023 and are encouraged by these early developments thus far in the year."

Unless otherwise indicated, all amounts are expressed in U.S. dollars. Certain metrics, including those expressed on an adjusted or comparable basis, are non-GAAP measures. See "Non-GAAP Measures" and "Selected Consolidated Financial Information" of this press release for further details.

**Investor Presentation**

Akumin would like to invite interested parties to an investor presentation to be held on Friday, March 17, 2023 from 8:30 a.m. to 9:30 a.m. Eastern Time where management will discuss fourth quarter and year-end results.

*Conference call details:*

Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8:30 a.m. Eastern Time, Friday, March 17, 2023

Click to join by phone:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>https://akum.in/2022-YearEndResults-Audio</u>

Access via webcast:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>https://akum.in/2022-YearEndResults-Webcast</u>

A related presentation will be available from Akumin's website (<u>www.akumin.com</u>) and at <u>https://akumin.com/investor-relations/events-presentations/</u>. Participants are asked to connect at least 10 minutes prior to the beginning of the call to ensure participation. The webcast archive will be available for 90 days. A replay of the presentation will also be available by calling 1-888-203-1112, or 647-436-0148 for international callers, using passcode 6212460.

**About Akumin**

Akumin is a national partner of choice for U.S. hospitals, health systems and physician groups, with comprehensive solutions addressing outsourced radiology and oncology service-line needs. Akumin provides (1) fixed-site outpatient diagnostic imaging services through a network of more than 180 owned and/or operated imaging locations; and (2) outpatient radiology and oncology services and solutions to

------

approximately 1,100 hospitals and health systems across 48 states. By combining clinical and operational expertise with the latest advances in technology and information systems, Akumin facilitates more efficient and effective diagnosis and treatment for patients and their providers. Akumin's imaging procedures include MRI, CT, positron emission tomography (PET and PET/CT), ultrasound, diagnostic radiology (X-ray), mammography, and other interventional procedures; cancer care services include a full suite of radiation therapy and related offerings. For more information, visit <u>www.akumin.com</u> and <u>www.alliancehealthcareservices-us.com</u>.

**Non-GAAP Measures**

This press release refers to certain non-GAAP measures. These non-GAAP measures are not recognized measures under United States generally accepted accounting principles ("<u>GAAP</u>") and do not have a standardized meaning prescribed by GAAP. Although the Company provides guidance for adjusted EBITDA, it is not able to provide guidance for net income, the most directly comparable GAAP measure. Certain elements of the composition of net income, including equity-based compensation, are not predictable, making it impractical for us to provide guidance on net income or to reconcile our adjusted EBITDA guidance to net income without unreasonable efforts. For the same reasons, the Company is unable to address the probable significance of the unavailable information regarding net income, which could be material to future results.

There is unlikely to be comparable or similar measures presented by other companies. Rather, these non-GAAP measures are provided as additional information to complement those GAAP measures by providing further understanding of our results of operations from management's perspective. Accordingly, these non-GAAP measures should not be considered in isolation nor as a substitute for analysis of our financial information reported under GAAP. We use non-GAAP financial measures, including "EBITDA", "Adjusted EBITDA" and "Adjusted EBITDA Margin" (each as defined below). These non-GAAP measures are used to provide investors with supplemental measures of our operating performance and thus highlight trends in our core business that may not otherwise be apparent when relying solely on GAAP measures. We believe the use of these non-GAAP measures, along with GAAP financial measures, enhances the reader's understanding of our operating results and is useful to us and to investors in comparing performance with competitors, estimating enterprise value, and making investment decisions. We also believe that securities analysts, investors, and other interested parties frequently use non-GAAP measures in the evaluation of issuers. Our management uses non-GAAP measures to facilitate operating performance comparisons from period to period, to prepare annual operating budgets and forecasts and to determine components of management compensation. Reconciliations of non-GAAP measures to the relevant reported measures can be found in "Reconciliation of Non-GAAP Financial Measures" and in our Form 10-K filed March 16, 2023 available in our public disclosure at <u>www.sec.gov</u> and <u>www.sedar.com</u>.

We define such non-GAAP measures as follows:

<u>"EBITDA"</u> means net income (loss) before interest expense (net), income tax expense (benefit), and depreciation and amortization.

<u>"Adjusted EBITDA"</u> means EBITDA, as further adjusted for impairment charges, restructuring charges, severance and related costs, settlements and related costs (recoveries), stock-based compensation, gain on sale of accounts receivable, losses (gains) on disposal of property and equipment, acquisition-related

------

costs, financial instrument revaluation adjustments, gain on conversion of debt to equity investment, deferred rent expense, other losses (gains), and one-time adjustments.

<u>"Adjusted EBITDA Margin"</u> means Adjusted EBITDA divided by the total revenue in the period.

**Forward-Looking Information**

Certain information in this press release constitutes forward-looking information or forward-looking statements. In some cases, but not necessarily in all cases, such statements or information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Akumin as of the date of this press release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of our Form 10-K filed March 16, 2023, which is available at <u>www.sec.gov</u> and <u>www.sedar.com</u>. These factors are not intended to represent a complete list of the factors that could affect Akumin; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this press release are made as of the date of this press release, and Akumin expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

**For further information:**

R. Jeffrey White<br>Investor Relations<br>1-866-640-5222<br>jeffrey.white@akumin.com

------

**Selected Consolidated Financial Information**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **(in thousands)** | **Three-month period<br>ended<br>Dec 31, 2022** | **Three-month period<br>ended<br>Dec 31, 2021** | <br>**$ Change** | <br>**% Change** |
| **Revenue** | $184635 | $179443 | $5192 | 3% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employee compensation | 65480 | 72684 | (7204) | -10% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reading fees | 11499 | 11200 | 299 | 3% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rent and utilities | 12601 | 12305 | 296 | 2% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third party services and professional fees | 31170 | 30337 | 833 | 3% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Administrative | 10085 | 11512 | (1427) | -12% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Medical supplies and other expenses | 17133 | 14455 | 2678 | 19% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 23195 | 24536 | (1341) | -5% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment charges | 26500 | - | 26500 | n/m |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring charges | 5259 | 1513 | 3746 | 248% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Severance and related costs | 608 | 1323 | (715) | -54% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Settlements, recoveries and related costs | 578 | (145) | 723 | -499% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 867 | 795 | 72 | 9% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other operating expense (income), net | (184) | 305 | (489) | -160% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense | 30362 | 28354 | 2008 | 7% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acquisition-related costs | 141 | 5821 | (5680) | -98% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other non-operating income, net | (620) | (528) | (92) | 17% |
| **Loss before income taxes** | (50039) | (35024) | (15015) | 43% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax expense (benefit) | (708) | (8392) | 7684 | -92% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Noncontrolling interests | (7721) | 5089 | (12810) | -252% |
| **Net loss attributable to common stockholders** | $(41610) | $(31721) | $(9889) | 31% |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **(in thousands)** | **Year<br>Ended<br>Dec 31, 2022** | **Year<br>Ended<br>Dec 31, 2021** | <br>**$ Change** | <br>**% Change** |
| **Revenue** | $749631 | $421079 | $328552 | 78% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employee compensation | 279906 | 160840 | 119066 | 74% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reading fees | 46164 | 42842 | 3322 | 8% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rent and utilities | 50715 | 37158 | 13557 | 36% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third party services and professional fees | 120441 | 60108 | 60333 | 100% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Administrative | 45706 | 27853 | 17853 | 64% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Medical supplies and other expenses | 65445 | 27566 | 37879 | 137% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 98205 | 44895 | 53310 | 119% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment charges | 47202 | - | 47202 | n/m |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring charges | 16625 | 1992 | 14633 | 735% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Severance and related costs | 10890 | 1376 | 9514 | 691% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Settlements, recoveries and related costs | 679 | (539) | 1218 | -226% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 3242 | 2792 | 450 | 16% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other operating expense (income), net | (7512) | 583 | (8095) | -1389% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense | 118012 | 62575 | 55437 | 89% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acquisition-related costs | 708 | 20233 | (19525) | -97% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other non-operating income, net | (3620) | (3990) | 370 | -9% |
| **Loss before income taxes** | (143177) | (65205) | (77972) | 120% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax expense (benefit) | 8410 | (30391) | 38801 | -128% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Noncontrolling interests | 5174 | 8477 | (3303) | -39% |
| **Net loss attributable to common stockholders** | $(156761) | $(43291) | $(113470) | 262% |

---

------

**Reconciliation of Non-GAAP Financial Measures**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **(in thousands)** | **Three-month period<br>ended<br>Dec 31, 2022** | **Three-month period<br>ended<br>Dec 31, 2021** | **Year<br>ended<br>Dec 31, 2022** | **Year<br>ended<br>Dec 31, 2021** |
| **Net loss** | $(49331) | $(26632) | $(151587) | $(34814) |
| Income tax expense (benefit) | (708) | (8392) | 8410 | (30391) |
| Depreciation and amortization | 23195 | 24536 | 98205 | 44895 |
| Interest expense | 30362 | 28354 | 118012 | 62575 |
| **EBITDA** | 3518 | 17866 | 73040 | 42265 |
| *Adjustments:* |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment charges | 26500 | - | 47202 | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring charges | 5259 | 1513 | 16625 | 1992 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Severance and related costs | 608 | 1323 | 10890 | 1376 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Settlements, recoveries and related costs | 578 | (145) | 679 | (539) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 867 | 795 | 3242 | 2792 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss (gain) on sale of accounts receivable | 219 | - | (7384) | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss (gain) on disposal of property and equipment, net | (225) | 427 | 173 | 748 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acquisition-related costs | 141 | 5821 | 708 | 20233 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fair value adjustment on derivative | (280) | (50) | (1390) | (100) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on conversion of debt to equity investment | - | - | - | (3360) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred rent expense | 301 | 277 | 1205 | 1802 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other, net | (105) | (305) | (888) | (306) |
| **Adjusted EBITDA** | $37381 | $27522 | $144102 | $66903 |
| **Revenue** | 184635 | 179443 | 749631 | 421079 |
| **Adjusted EBITDA Margin**<sup>(2)</sup> | 20% | 15% | 19% | 16% |

---

(1)Deferred rent expense is defined as operating lease cost less operating cash flows from operating leases and adjusted for any prepayments or related items.

(2)Adjusted EBITDA Margin is computed by dividing Adjusted EBITDA by the total revenue in the period.

<br>